Assessing the Feasibility and Acceptability of Raltegravir Granules for HIV Infected Neonates in Zimbabwe
Overview
Country:
Zimbabwe
Subject Matter:
Pediatric and Adolescent Testing, Care, and Treatment
This CDC-funded qualitative study explored the acceptability of using Raltegravir (RAL) granules for HIV-infected neonates among caregivers administering the drugs and healthcare workers in Zimbabwe. Interviews were conducted with caregivers of children on RAL, healthcare workers prescribing RAL, and Village Health Workers providing support to caregivers and the results were used to inform program and policy guidelines regarding the use of RAL at the facility, district, and national levels.
Data Collection Period: 06/2021 – 08/2021
Publications and Presentations:
- Paper published in BMJ Pediatrics Open, July 2022: “Optimising neonatal antiretroviral therapy using raltegravir: a qualitative analysis of healthcare workers’ and caregivers’ perspectives”
- Findings presented at the 24th International AIDS Conference, July 2022: “Acceptability of raltegravir granule use for neonates diagnosed with HIV at birth by healthcare workers and caregivers in Zimbabwe: A qualitative analysis”
- Paper published in the Pediatric Infectious Disease Journal, July 2023: “Implementation and Uptake of Raltegravir Granules in Newborns Diagnosed With HIV Through Birth Testing in Maternity Settings in Zimbabwe During the COVID-19 Pandemic”
